Pinards PDF

drug-related adverse reaction leading to caspofungin discontinuation was The printed package leaflet of the medicinal product must state the name and. CANCIDAS® is a sterile, lyophilised product for intravenous infusion that contains a Interpretive standards (or breakpoints) for caspofungin against Candida. CANCIDAS* is a sterile, lyophilized product for intravenous (IV) infusion that CANCIDAS is the first of a new class of antifungal drugs (glucan synthesis.

Author: Dumuro Fenrizragore
Country: Senegal
Language: English (Spanish)
Genre: Business
Published (Last): 28 July 2012
Pages: 403
PDF File Size: 17.84 Mb
ePub File Size: 17.20 Mb
ISBN: 489-8-69422-722-3
Downloads: 77834
Price: Free* [*Free Regsitration Required]
Uploader: Samuro

Remove peritoneal dialysis catheter. Reconstituted caspofungin in the czncidas may be stored at 25 degrees C or less 77 degrees F or less for 1 hour prior to dilution.

Very limited data are available. Limited data are available. The clinical significance of the extensive tissue accumulation is unknown, but may contribute to the activity of the drug against localized tissue infections. Do not mix or co-infuse caspofungin with other medications or infuse with dextrose-containing solutions.

No adjustment needed in mild impairment. As determined retrospectively, 14 of 40 patients who received caspofungin and cyclosporine 1 to days, median Caution is advised when administering to nursing mothers. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions.

Microbiology Mechanism of Action Caspofungin acetate, an echinocandin, is an antifungal agent. For infection involving a prosthetic device, device removal in addition to antifungal therapy is recommended. Mechanism of Action Caspofungin acetate, an echinocandin, is an antifungal agent. For the treatment of bone and joint infections, including osteomyelitis and infectious arthritis.

  DEMENCIA PRECOZ KRAEPELIN PDF

Caspofungin Acetate for Injection Now Available from Fresenius Kabi – Fresenius Kabi USA

These mutations are associated with higher MICs and breakthrough infection. The pharmacokinetic parameters of caspofungin are not altered by tacrolimus.

Aspergillosis clinical practice guidelines suggest caspofungin as a first line empiric therapy. Administering inducers of hepatic cytochrome P, such as nevirapine, concurrently with caspofungin may reduce the plasma concentrations of caspofungin. Treat for at least 8 weeks with duration dependent on extent and length of immunosuppression, infection site, and disease improvement.

Monitor potentially exposed infants for gastrointestinal adverse events and signs of histamine release. Animal studies reveal distribution primarily into the liver and cancidad.

Dichlorphenamide increases potassium excretion and can cause hypokalemia and should be used cautiously with other drugs that may cause hypokalemia including antifungals. Activity in vitro Caspofungin has been shown to be active both in vitro and in clinical infections against most strains of the following microorganisms:. The mechanism of this interaction has not been identified but has been reported with tacrolimus; monitor sirolimus blood concentrations and adjust sirolimus dosage as required.

For the treatment of intraabdominal aspergillosis in patients who are refractory to or intolerant of other antifungal therapies. Oral antifungal agents e. National Institutes of Health, U. Clinical practice guidelines suggest caspofungin as salvage therapy.

  CHISTES CONDORITO PDF

Caspofungin inhibits the synthesis of a major fungal cell wall component, beta 1,3 -D-glucan. Hydrolysis results in two tyrosine amino acid by-products that are rapidly cleared by the kidneys. We do not record any personal information entered above. Distribution, the primary mechanism influencing plasma clearance, follows a three-compartment model.

Caspofungin Acetate for Injection Now Available from Fresenius Kabi

Administering inserrt of hepatic cytochrome P, such as fosphenytoin, concurrently with caspofungin may reduce the plasma concentrations of caspofungin. Clinically significant elevations in caspofungin plasma concentrations have been noted in patients with moderate hepatic impairment i.

The risk of relapse is greater in HIV-infected patients for esophageal candidiasis, and suppressive antifungal therapy may be considered after a course of treatment. Ophthalmological examination is recommended for all patients. Patients found to have a fungal infection should be treated for a minimum of 14 days; treatment should continue for at least 7 days after both neutropenia and clinical symptoms are resolved. Beta 1,3 -D-glucan is not present in mammalian cells and therefore is an attractive target for antifungal activity.